More MS news articles for July 2001

IgG reactivity against citrullinated myelin basic protein in multiple sclerosis.

http://www.ncbi.nlm.nih.gov/cgi-bin/Entrez/referer?/htbin-post/Entrez/query_old%3fdb=m&form=6&uid=11431015&Dopt=r

J Neuroimmunol 2001 Jul 2;117(1-2):149-55

de Seze J, Dubucquoi S, Lefranc D, Virecoulon F, Nuez I, Dutoit V, Vermersch P, Prin L

Department of Immunology, CHRU of Lille, Lille, France

An increased level of citrullinated myelin basic protein (MBP-C8) has been reported in the brains of multiple sclerosis (MS) patients.

However, the involvement of the immune response to post-translational modified MBP in the pathophysiology of MS remains speculative.

The aim of this study was to compare the levels of immunoglobulin G antibodies to several MBP epitopes, before and after citrullination, in the cerebrospinal fluid (CSF) and sera of MS patients using enzyme-linked immunosorbent assay (ELISA).

We analyzed antibody reactivity against various MBP-peptides in the CSF and sera of 60 MS patients, and 30 patients with other neurological diseases (OND) as controls.

The peptides tested were: MBP(75-98) (peptide 1), native (peptide 2) and citrullinated (peptide 3) MBP(108-126) (ARG(122)-->Cit(122)), and native (peptide 4) and citrullinated (peptide 5) MBP(151-170) (ARG(159, 170)-->Cit(159, 170)).

All selected peptides could support an immune reactivity in CSF and sera of MS and OND patients.

A higher reactivity against peptide 4 was found in the CSF of MS patients compared with OND patients (P<0.0001), but not against citrullinated peptides (peptides 3 and 5).

However, we observed that the citrullination state of peptide 2 modified the patterns of immune reactivity more markedly in MS patients (P<0.0001) than in OND patients (P<0.02).

Although some MBP epitopes could be a potential target in MS, our data did not demonstrate any difference of antibody response to MBP peptides in their citrullinated forms.

PMID: 11431015, UI: 21324605